Signals, Powered By EquityPandit
The Japanese subsidiary of Lupin, Kyowa Pharmaceutical Industry Co Ltd has signed an agreement with Astellas Pharma Inc for exclusive right of distributing and promoting extended-release tablets of quetiapine fumarate in Japan.
Lupin has said in a BSE filing that “Its Japanese subsidiary Kyowa Pharmaceutical Industry Co, Ltd and Astellas Pharma Inc have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan.”
It added that “Astellas submitted a new drug application (NDA) with the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine furmarate for the indication of improvement of depressive symptoms associated with bipolar disorder.”
